Empros Pharma AB   Report issue

For profit Phase 2
Founded: Solna Sweden (2013)

Organization Overview

First Clinical Trial
2020
NCT04521751
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Empros Pharma AB

Active Ingredients

Drugs in Phase 2 Trials (2)

acarbose (precose) (1 trial)

orlistat (xenical) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Body Weight (Phase 2)

Overweight (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2